Innovent Biologics (HKG:1801) recorded a total product revenue of over 2.4 billion yuan in the first quarter, up 40% from a year prior, a Thursday Hong Kong bourse filing said.
The drugmaker launched four new products in the quarter, comprising Dovbleron, Limertinib, and Jaypirca in the oncology niche, and SYCUME in the field of general biomedicine.
To date, the company has 15 approved products, three new drug applications under regulatory review, four assets in phase III or pivotal clinical trials, and 15 more molecules in early clinical stage.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.